Brought to you by 
MorphoSys nets $222mm through IPO on Nasdaq
03 May 2018
Executive Summary
Public German biotech MorphoSys AG (antibody therapeutics and technologies) netted $222.3mm in its initial public offering on the Nasdaq Exchange of 9.545mm American Depositary Shares (including the overallotment) at $25.04. Since each ADS is equivalent to 0.25 of an ordinary share, this equates to 2.39mm ordinary shares at $100.16 apiece.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MorphoSys nets $222mm through IPO on Nasdaq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice